ProCE Banner Activity

CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC

Slideset Download
Conference Coverage
In a post hoc analysis of CheckMate 816, pCR or major pathologic response in the primary tumor was associated with improved EFS with neoadjuvant nivolumab + chemotherapy and chemotherapy in resectable NSCLC.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab